Experimental mRNA cancer vaccine cuts melanoma recurrence risk by 42%

Moderna and Merck published Thursday data showing their personalized mRNA vaccine, added to Keytruda, cut the risk that melanoma returns by 42%.

• Moderna and Merck published Thursday data showing their experimental vaccine cut the risk of melanoma returning or causing death by 42% versus Keytruda alone.
• The vaccine, named Intes Miran, is personalized to each patient's tumor and uses the same mRNA technology as COVID-19 shots.
• Results will be presented Saturday in Madrid at a European Society for Medical Oncology meeting.
• Trials are underway testing similar personalized mRNA vaccines against lung, kidney and pancreatic cancers.